Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prestara for bone loss prevention in women with SLE on glucocorticoids
NCT00082511Phase 3Completed
- Sponsor
- Genelabs Technologies
- Start
- Jul 2003
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of prasterone in systemic lupus erythematosus (SLE) (4 arms), sponsored by Genelabs Technologies. Primary endpoint: Bone Mineral Density at 12 months. Started Jul 2003; status: completed.
02
Drugs
prasterone
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00082511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082511.